Insider Transactions in Q1 2024 at Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Stephanie Okey |
SELL
Open market or private sale
|
Direct |
17,500
-74.47%
|
$805,000
$46.38 P/Share
|
|
Mar 28
2024
|
Stephanie Okey |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+42.68%
|
$315,000
$18.29 P/Share
|
|
Mar 22
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
32,359
-19.81%
|
$1,423,796
$44.81 P/Share
|
|
Mar 22
2024
|
Jeff E. Knight Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+26.1%
|
$690,000
$23.98 P/Share
|
|
Mar 20
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
15,089
-13.93%
|
$663,916
$44.29 P/Share
|
|
Mar 20
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+16.18%
|
$230,000
$16.89 P/Share
|
|
Mar 20
2024
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
60,000
-44.42%
|
$2,640,000
$44.06 P/Share
|
|
Mar 20
2024
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+30.7%
|
$1,260,000
$21.25 P/Share
|
|
Mar 19
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
6,942
-5.9%
|
$291,564
$42.91 P/Share
|
|
Mar 18
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,283
-7.23%
|
$162,754
$38.14 P/Share
|
|
Mar 18
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
411
-1.42%
|
$15,618
$38.14 P/Share
|
|
Mar 18
2024
|
Richard Scott Struthers President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,687
-5.06%
|
$482,106
$38.14 P/Share
|
|
Mar 18
2024
|
Marc Wilson CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,983
-3.28%
|
$151,354
$38.14 P/Share
|
|
Mar 18
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,655
-3.8%
|
$138,890
$38.14 P/Share
|
|
Mar 18
2024
|
James Hassard Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,741
-5.62%
|
$66,158
$38.14 P/Share
|
|
Mar 04
2024
|
James Hassard Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+35.42%
|
-
|
|
Mar 04
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+44.31%
|
-
|
|
Mar 04
2024
|
Richard Scott Struthers President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+20.6%
|
-
|
|
Mar 04
2024
|
Marc Wilson CFO |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+17.34%
|
-
|
|
Mar 04
2024
|
Stephen F. Betz Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+19.28%
|
-
|
|
Mar 04
2024
|
Jeff E. Knight Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+27.97%
|
-
|
|
Feb 12
2024
|
Richard Scott Struthers President & CEO |
BUY
Bona fide gift
|
Indirect |
60,000
+15.38%
|
-
|
|
Feb 12
2024
|
Richard Scott Struthers President & CEO |
SELL
Bona fide gift
|
Indirect |
60,000
-9.51%
|
-
|
|
Jan 25
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.93%
|
$111,000
$37.26 P/Share
|
|
Jan 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.78%
|
$111,000
$37.65 P/Share
|
|
Jan 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-70.86%
|
$503,125
$35.0 P/Share
|
|
Jan 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+41.47%
|
$230,000
$16.89 P/Share
|
|
Jan 02
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
10,000
-9.43%
|
$350,000
$35.47 P/Share
|
|
Jan 02
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.62%
|
$90,000
$9.28 P/Share
|